ABPI names 5 pharmas as code-breachers; Teva wins 180-day marketing exclusivity for Evista generic;

> Lundbeck, Menarini, Bayer, HRA Pharma UK and GlaxoSmithKline ($GSK) have breached the Association of British Pharmaceutical Industries' code of practice. More

> Teva ($TEVA) has received U.S. approval for a generic of Eli Lilly's ($LLY) Evista tablets, winning the first-to-file 180 day market exclusivity. Release

> Physicians Interactive and McKesson ($MCK) are teaming up to provide Coupons on Demand, which grants healthcare providers access to medication cost-savings offers through an Internet platform. Release

> Sanofi ($SNY) is suing Actavis ($ACT) over allegedly infringing patents on its heart drug Multaq. Report | Release

> AstraZeneca ($AZN) has won U.S. approval for a pen-injector version of once-weekly diabetes med Bydureon. News

> Newcastle, U.K.-based remarketing agency, has won a contract with Fertin Pharma, the world's largest medical chewing gum maker. Report

And Finally... Prospects for Gilead's ($GILD) next-generation hepatitis C drug Sovaldi have made CEO John Martin a billionaire. More

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

The Tecentriq-Avastin-chemo cocktail did slightly better in PD-L1-positive patients but still failed to cross the statistical significance bar.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.